Physician profile
Nicholas Devito
NPI 1962758060
$8,491.36
in general payments reported to CMS, 2019-2025
6 companies · $6,180 in 2025
The $6,180 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2022: $229 · 2024: $14.26 · 2025: $6,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,675 · Travel and Lodging: $1,414 · Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,675.00 |
| Travel and Lodging | $1,413.71 |
| Food and Beverage | $105.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $6,162.57 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,920.00 | 2019 | |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Eli Lilly and Company | $148.07 | 2019 | |
| Caris Mpi, INC. | $17.46 | 2025 | Mi Cancer Seek |
| Beigene USA, INC. | $14.26 | 2024 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Devito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.